Lanreotide
Also known as: BIM-23014, Lanreotide acetate, Somatuline, Somatuline Autogel, Somatuline Depot, Somatuline LA
Source Lanreotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lanreotide is a synthetic cyclic octapeptide somatostatin analogue used by deep subcutaneous injection to control acromegaly and to manage symptoms of gastroenteropancreatic neuroendocrine tumors.
Mechanism of Action
binds to somatostatin receptors (primarily SSTR2 and SSTR5) leading to inhibition of growth hormone, insulin, glucagon, and gastrointestinal hormone secretion; also exerts antiproliferative effects on neuroendocrine tumors.
Routes of Administration
Goals & Uses
- Acromegaly managementEndocrinologyHigh
- Carcinoid syndrome symptom controlOncology/GastroenterologyHigh
- Inhibition of tumor growthOncologyModerate
- Polycystic liver disease volume reductionHepatologyModerate
- Thyroid-stimulating hormone (TSH)-secreting pituitary adenomaEndocrinologyModerate
- Symptom control of neuroendocrine tumorsNETHigh
- GEP-NET tumor controlOncologyHigh
- Control of excess GH/IGF‑1AcromegalyHigh
Contraindications
- Severe gallbladder diseaseGastrointestinalModerate
- Hypersensitivity to lanreotide or any excipientsAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
- Hypersensitivity to lanreotide or excipientsAllergyHigh
Adverse Effects
- Gallstones / biliary sludgeGastrointestinal/HepatobiliaryCommon
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Hyperglycemia or hypoglycemiaMetabolic/EndocrineUncommon
- Injection site reactionsLocalCommon
- Abdominal pain/discomfortGastrointestinalCommon
- Gallstones/cholelithiasisGastrointestinalUncommon
- Abdominal pain/crampingGastrointestinalCommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
- BradycardiaCardiovascularUncommon
Drug Interactions
- QT-prolonging drugsModerate
- Cytochrome P450 substratesLow
- Insulin / Oral antidiabeticsModerate
- CyclosporineModerate
- BromocriptineLow
- Antidiabetic agents (e.g., insulin, sulfonylureas)Moderate
Population Constraints
- Pediatric patientsAgeAbsolute
- Patients with hepatic impairmentOrgan FunctionRelative
- Patients with cardiac disease (bradycardia, conduction disorders)CardiovascularRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
- Diabetic PatientsMetabolicRelative
- Renal impairment (eGFR <30 mL/min)RenalRelative
Regulatory Status
- European UnionApprovedApproved: acromegaly, neuroendocrine tumor symptom controlEMA approval for same indications.
- United StatesApprovedApproved: acromegaly, gastroenteropancreatic neuroendocrine tumorsFDA approved as Somatuline Autogel.
- United KingdomApprovedApproved: acromegaly, NET symptom controlMHRA approved.
Approved in the US (FDA) and EU (EMA) for acromegaly and for symptom control of gastroenteropancreatic neuroendocrine tumors. Marketed as Somatuline Autogel/Depot.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Lanreotide?
Lanreotide is a synthetic cyclic octapeptide somatostatin analogue used by deep subcutaneous injection to control acromegaly and to manage symptoms of gastroenteropancreatic neuroendocrine tumors.
What is Lanreotide used for?
Lanreotide is educationally associated with: Acromegaly management, Carcinoid syndrome symptom control, Inhibition of tumor growth, Polycystic liver disease volume reduction, Thyroid-stimulating hormone (TSH)-secreting pituitary adenoma, Symptom control of neuroendocrine tumors, GEP-NET tumor control, Control of excess GH/IGF‑1. Educational only — not medical advice.
How is Lanreotide administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Lanreotide?
Reported adverse effects include: Gallstones / biliary sludge, Hyperglycemia, Hyperglycemia or hypoglycemia, Injection site reactions, Abdominal pain/discomfort, Gallstones/cholelithiasis, Abdominal pain/cramping, Diarrhea, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lanreotide?
Recorded contraindications: Severe gallbladder disease, Hypersensitivity to lanreotide or any excipients, Pregnancy, Breastfeeding, Hypersensitivity to lanreotide or excipients. Consult a qualified clinician before use.